An interesting observation from Paul Elliott of the Motley Fool on Martha Stewart's guilty verdict:

The nightmare began back in Dec. 2001, when, on hearing from her broker that then-CEO Sam Waksal was selling stock (Waksal himself had heard that bad tidings were a-brewing at the FDA over cancer drug Erbitux), Stewart dumped some middling number of ImClone shares. The price? Somewhere in mid-$50s. The irony? After a harrowing ride to the single digits, ImClone closed today at around $47.50, within a hair of its 52-week highs.